Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

• Published in: Journal of pain research 2019-05, Vol.12, p.1631-1648
• Main Authors: Akazawa, Manabu, Mimura, Wataru, Togo, Kanae, Ebata, Nozomi, Harada, Noriko, Murano, Haruka, Abraham, Lucy, Fujii, Koichi
• Format: Article
• Language: English
• Subjects: Acetaminophen; Analgesics; Back pain; chronic low back pain; COX-2 inhibitors; Disabilities; Drugs; Duloxetine; Health care costs; Hyaluronic acid; Medical economics; non-steroidal anti-inflammatory drugs; opioid; Opioids; Original Research; Osteoarthritis; pain; Pregabalin; Prescriptions (Drugs); Production management; Steroidal anti-inflammatory agents
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S203553

Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings. A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP. The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4%; CLBP: +14.4%) increased between 2013 and 2017. The first commonly prescribed medication among patients with OA and CLBP were NSAIDs; hyaluronate injection (patients with OA) and pregabalin (patients with CLBP) were also common first-line medications. Acetaminophen, steroid injection (patients with OA), and weak opioids were prescribed more in the later phases of treatment. Most patients were prescribed limited classes of pain drugs, with NSAIDs being the most common pain medication in Japan for patients with OA and CLBP. Opioid prescription was uncommon, and were weak opioids when prescribed.